PubMed

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.

Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators.

Neurology. 2009 Nov 3;73(18):1493-500.PMID: 19884577 [PubMed - indexed for MEDLINE]Related articles

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Pachner AR, Cadavid D, Wolansky L, Skurnick J.

Neurology. 2009 Nov 3;73(18):1485-92.PMID: 19884576 [PubMed - indexed for MEDLINE]Related articles

Resistance training improves muscle strength and functional capacity in multiple sclerosis.

Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T.

Neurology. 2009 Nov 3;73(18):1478-84.PMID: 19884575 [PubMed - indexed for MEDLINE]Related articles

First oral therapies for multiple sclerosis anticipated.

Hughes B.

Nat Rev Drug Discov. 2009 Nov;8(11):831-3. No abstract available. PMID: 19876030 [PubMed - indexed for MEDLINE]Related articles

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group.

Ann Neurol. 2009 Oct;66(4):460-71.PMID: 19847908 [PubMed - indexed for MEDLINE]Related articles

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

Hartung HP, Aktas O.

Ann Neurol. 2009 Oct;66(4):429-32. No abstract available. PMID: 19847907 [PubMed - indexed for MEDLINE]Related articles

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group.

Ann Neurol. 2009 Oct;66(4):513-20.PMID: 19847899 [PubMed - indexed for MEDLINE]Related articles

Revolutionary advances in the prevention of demyelinating diseases.

Edlich R, Mason SS, Chase ME, Fisher AL, Gubler K, Long WB 3rd, Newkirk AT.

J Environ Pathol Toxicol Oncol. 2009;28(2):143-52. Review.PMID: 19817701 [PubMed - indexed for MEDLINE]Related articles

Treatment of clinically isolated syndrome: to be PreCISe.

Miller DH, Leary SM.

Lancet. 2009 Oct 31;374(9700):1475-6. Epub 2009 Oct 6. Review. No abstract available. PMID: 19815269 [PubMed - indexed for MEDLINE]Related articles

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group.

Lancet. 2009 Oct 31;374(9700):1503-11. Epub 2009 Oct 6.PMID: 19815268 [PubMed - indexed for MEDLINE]Related articles

A review of multiple sclerosis with Asian perspective.

Chong HT, Tan CT.

Med J Malaysia. 2008 Dec;63(5):356-61. Review.PMID: 19803290 [PubMed - indexed for MEDLINE]Related articles

Interferon-beta therapy for multiple sclerosis--is the injection site the relevant action site?

Smith D.

J Neuroimmunol. 2009 Oct 30;215(1-2):117-21. Epub 2009 Sep 20. Review.PMID: 19773087 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

Singhal BS, Geeta S, Hundalani SG, Menon S.

Neurol India. 2009 Jul-Aug;57(4):418-23.PMID: 19770542 [PubMed - indexed for MEDLINE]Related articlesFree article

The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

Klawiter EC, Cross AH, Naismith RT.

Neurology. 2009 Sep 22;73(12):984-90.PMID: 19770475 [PubMed - indexed for MEDLINE]Related articles

Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.

Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, Lanker S, Bourdette D.

J Neuroimmunol. 2009 Oct 30;215(1-2):125-8. Epub 2009 Sep 15.PMID: 19758707 [PubMed - indexed for MEDLINE]Related articles

Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica.

Cayrol R, Saikali P, Vincent T.

Ann N Y Acad Sci. 2009 Sep;1173:478-86. Review.PMID: 19758189 [PubMed - indexed for MEDLINE]Related articles

Comparing individualized rehabilitation to a group wellness intervention for persons with multiple sclerosis.

Plow MA, Mathiowetz V, Lowe DA.

Am J Health Promot. 2009 Sep-Oct;24(1):23-6.PMID: 19750959 [PubMed - indexed for MEDLINE]Related articles

Uncertain BENEFIT of early interferon beta-1b treatment.

Pittock SJ.

Lancet Neurol. 2009 Nov;8(11):970-1. Epub 2009 Sep 10. No abstract available. PMID: 19748320 [PubMed - indexed for MEDLINE]Related articles

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Lancet Neurol. 2009 Nov;8(11):987-97. Epub 2009 Sep 10.PMID: 19748319 [PubMed - indexed for MEDLINE]Related articles

Pathogenic CD8(+) T cells in multiple sclerosis.

Friese MA, Fugger L.

Ann Neurol. 2009 Aug;66(2):132-41. Review.PMID: 19743458 [PubMed - indexed for MEDLINE]Related articles